In present-day world intestinal parasitic infections are gaining importance as a cause of morbidity and mortality. One of the reasons behind it is the globalization and increased number of people travelling to endemic areas of parasitic diseases. Consequently, we need to treat increasing number of patients showing symptoms of such diseases. Unfortunately, the array of available and efficient antiparasitic drugs has been shrinking. Their efficacy decreases and quite often the side effects are serious. In this paper we would like to focus on a new promising "nitazoxanide" (active substance). "Nitazoxanide" proved its efficacy in the treatment of nematode-, cestode-, trematode- and protozoan infections.